Maze Therapeutics is like a **Vertex Pharmaceuticals** focused on developing precision medicines for kidney and metabolic diseases, leveraging deep genetic insights.

• MZE829: An oral, small molecule inhibitor of apolipoprotein L1 (APOL1) for the treatment of APOL1 kidney disease (AKD).
• MZE782: An oral, small molecule inhibitor of the solute transporter SLC6A19, primarily aimed at chronic kidney disease (CKD) with potential for phenylketonuria (PKU).

Maze Therapeutics (MAZE) is a clinical-stage biopharmaceutical company focused on the research and development of novel precision medicines. As such, the company is currently engaged in clinical trials for its drug candidates (MZE829 and MZE782) and does not yet have any commercialized products on the market. Therefore, Maze Therapeutics does not have major customers at this time, as it is not currently selling products to other companies or individuals.

Jason Coloma, Chief Executive Officer

Dr. Jason Coloma is the Chief Executive Officer of Maze Therapeutics. He was previously the company's chief operating officer and a venture partner at Third Rock Ventures, where he played a key role in the founding and launch of Maze. Prior to Maze, he served as interim Chief Business Officer at Third Rock portfolio companies insitro and Celsius. His career also includes roles as Senior Vice President and Chief Business Officer at Corvus Pharmaceuticals, and Vice President & Global Therapeutic Area Head of Oncology and Cancer Immunotherapy Partnering at Roche. He also worked as a consultant in the life sciences practice at L.E.K. Consulting. Maze Therapeutics was launched in 2019 by Third Rock Ventures and received funding from various investors, including ARCH Venture Partners and GV.

Misbah Tahir, Chief Financial Officer

Misbah Tahir was appointed Chief Financial Officer of Maze Therapeutics in September 2025. He brings over two decades of financial and strategic leadership experience in the biopharmaceutical industry. Most recently, he served as Chief Financial Officer at IGM Biosciences, Inc., where he was instrumental in guiding the company through its 2019 initial public offering and helped raise more than $1 billion through equity financings and a pharmaceutical partnership. Tahir began his career in the biopharmaceutical sector at Amgen, Inc. after working as a management consultant.

Harold Bernstein, President, Research and Development and Chief Medical Officer

Dr. Harold Bernstein joined Maze Therapeutics as President, Research and Development and Chief Medical Officer in 2022. He has over three decades of experience in scientific research, translational medicine, and clinical development in both industry and academia. Before Maze, he was Senior Vice President, Chief Medical Officer, and Head of Global Clinical Development at BioMarin Pharmaceutical. His previous roles include Head of Translational Medicine and Vice President of Global Medicines Development and Medical Affairs at Vertex Pharmaceuticals, and positions at Merck, where he was head of early development for cardiometabolic diseases. Dr. Bernstein also held academic positions as a professor of pediatrics and a senior investigator at the University of California, San Francisco (UCSF), and served as an attending physician at UCSF Benioff Children's Hospital and Mount Sinai Kravis Children's Hospital.

Atul Dandekar, Chief Strategy & Business Officer

Atul Dandekar serves as the Chief Strategy & Business Officer for Maze Therapeutics.

Courtney Phillips, General Counsel & Corporate Secretary

Courtney Phillips is the General Counsel & Corporate Secretary at Maze Therapeutics.

• Clinical Trial Failure: As a clinical-stage biopharmaceutical company, Maze Therapeutics' success is fundamentally dependent on the successful outcome of its ongoing and future clinical trials for its lead product candidates, MZE829 and MZE782. Both programs are currently in early to mid-stage clinical development (Phase 1 and Phase 2 respectively), and there is a significant risk that these trials may not demonstrate sufficient safety or efficacy, or may encounter unexpected adverse events, which could lead to delays, termination, or failure to achieve regulatory approval.
• Reliance on Novel Platform and Mechanisms of Action: Maze Therapeutics' strategy hinges on its proprietary Compass platform and its approach of "variant functionalization" to develop precision medicines that phenocopy protective genetic variants. The company's lead programs, MZE829 (targeting APOL1) and MZE782 (targeting SLC6A19), represent novel mechanisms of action for chronic kidney disease. There is a risk that this innovative platform may not consistently identify viable drug candidates, or that the specific therapeutic hypotheses underlying their lead programs may not translate into robust clinical benefits, potentially undermining their entire development pipeline.
• Regulatory Approval Risk: Even if clinical trials for MZE829 and MZE782 are successful, Maze Therapeutics faces the significant challenge and inherent uncertainty of obtaining regulatory approvals from agencies like the FDA. The regulatory process is rigorous and can be unpredictable, especially for novel precision medicines utilizing new mechanisms. Delays in the approval process or a failure to obtain necessary approvals could significantly impact the company's ability to commercialize its products and generate revenue.

For Maze Therapeutics' lead programs, the addressable markets are as follows:

• MZE829: Estimated to affect over one million patients with APOL1 kidney disease (AKD) in the United States.
• MZE782: Has the potential to address approximately five million chronic kidney disease (CKD) patients in the United States with inadequate responses to currently available therapies.

The expected drivers of future revenue growth for Maze Therapeutics (MAZE) over the next 2-3 years are primarily centered on the advancement and potential success of its lead clinical programs and the expansion of its pipeline:

1. Advancement and Positive Clinical Trial Results for MZE829 in APOL1 Kidney Disease (AKD): Maze Therapeutics anticipates dosing the first patient in its Phase 2 trial for MZE829 in AKD during the first quarter of 2025 and reporting proof-of-concept data in the first quarter of 2026. Successful progression through this clinical stage, demonstrating efficacy and safety, would significantly de-risk the program, enhance its market potential, and represent a key step towards future commercialization for a disease affecting over one million patients in the United States.
2. Advancement and Initial Clinical Trial Results for MZE782 in Chronic Kidney Disease (CKD): The company initiated a Phase 1 trial for MZE782 in September 2024 and expects to report initial data in the second half of 2025. Positive results from this trial would enable progression to later clinical stages, validating MZE782 as a potential novel treatment for approximately five million CKD patients in the United States who currently have inadequate responses to available therapies.
3. Expansion of MZE782 into Phenylketonuria (PKU): Following the ongoing Phase 1 trial for MZE782 in CKD, Maze Therapeutics plans to conduct a parallel Phase 2 clinical trial to explore MZE782 as a potential treatment for phenylketonuria. This strategic move into a new, genetically defined metabolic disease represents a significant market expansion opportunity for MZE782, diversifying its potential revenue streams beyond CKD.
4. Pipeline Expansion through the Compass Platform: Maze Therapeutics' proprietary Compass platform is designed to identify and characterize genetic variants to develop novel precision medicines. The continued successful application of this platform to generate new lead programs and expand the company's pipeline beyond MZE829 and MZE782 will be crucial for long-term revenue growth. This platform underpins the company's ability to consistently discover and advance new drug candidates.

Share Issuance

• Maze Therapeutics completed its Initial Public Offering (IPO) on January 31, 2025, raising approximately $140 million in gross proceeds by offering 8,750,000 shares of common stock at $16.00 per share.
• The company conducted an oversubscribed private placement in September 2025, which raised approximately $150.0 million through the issuance of 4,000,002 shares of common stock at a price of $16.25 per share.

Inbound Investments

• Prior to its IPO, Maze Therapeutics raised almost $500 million in private funding, which included a $190 million funding round in 2022 and a $115 million Series D financing in December 2024.
• In the first half of 2024, Maze Therapeutics recognized $165.0 million in license revenue, with $150.0 million from an exclusive license agreement with Shionogi & Co., Ltd. for MZE001 and an additional $15.0 million from Trace Neuroscience, Inc.

Capital Expenditures

• Proceeds from financing rounds, including the September 2025 private placement, are intended to advance the development of lead programs MZE829 and MZE782 in clinical trials, further develop its Compass platform, and cover general corporate purposes.